Depression: Treating the patient with comorbid cardiac disease

Geriatrics

Volumn 54, Issue 2, 1999, Pages 20-35

  Roose, Steven P ^a   Devanand, Davangere ^a   Suthers, Kristen ^b  

^a Columbia UNiversity ^*  (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; FLUOXETINE; PAROXETINE; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANTIARRHYTHMIC ACTIVITY; CARDIOTOXICITY; COMORBIDITY; DEPRESSION; DRUG EFFECT; DRUG SAFETY; HEART INNERVATION; HUMAN; ISCHEMIC HEART DISEASE; ORTHOSTATIC HYPOTENSION; PSYCHOPHARMACOTHERAPY; REVIEW; TREATMENT PLANNING;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CARDIOVASCULAR DISEASES; COMORBIDITY; DEPRESSIVE DISORDER; HEMODYNAMIC PROCESSES; HUMANS; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 0032940181     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Malzberg B. Mortality among patients with involution melancholia. Am J Psychiatry 1937; 93:1231-8.
2. Black DW, Warrack G, Winokur G. The Iowa record-linkage study: III. Excess mortality among patients with 'functional' disorders. Arch Gen Psychiatry 1985; 42:82-8.
3. Weeke A. Causes of death in manic-depressives. In: Schou M, Stromgren E (eds). Origin, prevention and treatment of affective disorders. London: Academic Press, 1979:289-99.
4. Avery D, Winokur G. Mortality in depressed patients treated with electroconvulsive therapy and antidepressants. Arch Gen Psychiatry 1976; 33:1029-37.
5. Glassman AH, Helzer JE, Covey LS, et al. Smoking, smoking cessation, and major depression. JAMA 1990; 264:1546-9.
6. Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW. Depression, psychotropic medication, and risk of myocardial infarction: Prospective data from the Baltimore ECA follow-up. Circulation 1996; 94:3123-9.
7. Glassman AH, Shapiro PA Depression and the course of coronary artery disease. Am J Psychiatry 1998; 155:4-11.
8. Carney RM, Rich MW, Freedland KE, et al. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 1988; 50:627-33.
9. Schleifer SJ, Macari-Hinson MM, Coyle DA, et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989; 149:1785-9.
10. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: Impact on 6-month survival. JAMA 1993; 270:1819-25.
11. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995; 91:999-1005.
12. Lown B. Sudden cardiac death: Biobehavioral perspective. Circulation 1987; 76 (1,pt.2):I186-I196.
13. Kliks BR, Burgess MJ, Abildskov JA. Influence of sympathetic tone on ventricular fibrillation threshold during experimental coronary occlusion. Am J Cardiol 1975; 36:45-9.
14. Carney RM, Rich MW, Tevelde A, Saini J, Clark K, Freedland KE. The relationship between heart rate, heart rate variability and depression in patients with coronary artery disease. J Psychosom Res 1988; 32:159-64.
15. Kleiger RE, Miller JP, Bigger JT, Jr., Moss AJ, Multicenter Post-Infarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59:256-62.
16. Yeragani VK, Pohl RB, Balon R, et al. Heart rate variability in patients with major depression. Psychiatry Res 1991; 37:35-46.
17. Roose SP, Dalack GW. Treating the depressed patient with cardiovascular problems. J Clin Psychiatry 1992; 53(Sept [suppl]):25-31.
18. Lesperance F, Frasure-Smith N, Talajic M. Major depression before and after myocardial infarction: Its nature and consequences. Psychosom Med 1996; 58:99-110.
19. Roose SP, Glassman AH. Cardiovascular effects of tricyclic antidepressants in depressed patients with and without heart disease. J Clin Psychiatry 1989; 50[suppl]:1-18.
20. Glassman AH, Roose SP, Bigger JT Jr. The safety of tricyclic antidepressants in cardiac patients: Risk/benefit reconsidered. JAMA 1993; 269:2673-5.
21. Furberg CD. Effect of antiarrhythmic drugs on mortality after myocardial infarction. Am J Cordial 1983; 52:32C-36C.
22. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321:406-12.
23. Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327:227-33.
24. Falk RH. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989; 111:107-11.
25. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials. Circulation 1990; 82:1106-16.
26. Greenberg HM, Dwyer EM, Jr., Hochman JS, Steinberg JS, Echt DS, Peters RW. Interaction of ischaemia and encainide/flecainide treatment: A proposed mechanism for the increased mortality in CAST I. Br Heart J 1995; 74:631-5.
27. Roose SP, Glassman AH, Attia E, Woodring S, Giardina EGV, Bigger JT Jr. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998; 155(5):660-5.
28. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998; 279:287-91.
29. Shapiro PA, Glassman AH, Lesperance F, et al. Treatment of major depression after acute myocardial infarction with sertraline: A preliminary study. New York: Proceedings of the American Psychiatric Association, 1996:249-50.
30. Roose SP, Glassman AH, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994; 151:1735-9.